

Resource Summary Report

Generated by [nidm-terms](#) on Jul 30, 2026

Illumina

RRID:SCR_010233

Type: Tool

Proper Citation

Illumina (RRID:SCR_010233)

Resource Information

URL: <http://www.illumina.com/>

Proper Citation: Illumina (RRID:SCR_010233)

Description: American company incorporated that develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function. Provides a line of products and services that serve the sequencing, genotyping and gene expression and proteomics markets. Its headquarters are located in San Diego, California.

Abbreviations: Illumina, Inc.

Synonyms: Inc., Illumina

Resource Type: commercial organization

Keywords: Commercial, organization, develop, manufacture, system, analysis, genetic, sequencing, genotyping, gene, expression, proteomic

Resource Name: Illumina

Resource ID: SCR_010233

Alternate IDs: nlx_156846, grid.185669.5, Wikidata: Q2068984, ISNI: 0000 0004 0507 3954

Alternate URLs: <https://ror.org/05k34t975>

Record Creation Time: 20220129T080257+0000

Record Last Update: 20260725T190658+0000

Ratings and Alerts

No rating or validation information has been found for Illumina.

No alerts have been found for Illumina.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2340 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Camerini L, et al. (2026) Harsh parenting and rs11621961 at the SERPINA6/1 locus: gene-environment interaction effects on hair cortisol in a Brazilian population-based longitudinal study. *Stress (Amsterdam, Netherlands)*, 29(1), 2611613.

Torozan DA, et al. (2025) Metagenomic Profiling of Oral Microbiome Dynamics During Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Patients. *Cancer medicine*, 14(1), e70589.

Lee SM, et al. (2025) Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 848.

Chen XX, et al. (2025) Microbial dysbiosis with tryptophan metabolites alteration in lower respiratory tract is associated with clinical responses to anti-PD-1 immunotherapy in advanced non-small cell lung cancer. *Cancer immunology, immunotherapy : CII*, 74(4), 140.

Lee LH, et al. (2025) Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data. *Cancer research communications*, 5(6), 1049.

Diamond B, et al. (2025) Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies. *Blood cancer discovery*, 6(5), 450.

Tesi B, et al. (2025) Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(14), 3062.

Lu H, et al. (2025) Epithelial-Mesenchymal Transition is Associated with Altered Immune Composition and Cytotoxic Function in Triple-Negative Breast Cancer. *bioRxiv : the preprint server for biology*.

Cluzet V, et al. (2025) Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways. *Molecular*

cancer therapeutics, 24(8), 1197.

Yuan T, et al. (2025) Methylation-based alcohol consumption scores as prognostic biomarkers in colorectal cancer: Insights from a population-based cohort. *International journal of cancer*.

Collet L, et al. (2025) Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(15), 3317.

Huffmyer AS, et al. (2025) Shifts and critical periods in coral metabolism reveal energetic vulnerability during development. *Current biology : CB*, 35(12), 2858.

Vander Donck L, et al. (2025) Host-independent synergism between *Lactobacillus crispatus* and other vaginal lactobacilli. *Cell reports*, 44(9), 116171.

Hassan AM, et al. (2025) Ongoing Evolution of Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, 2023-2024. *Emerging infectious diseases*, 31(1), 57.

Pu G, et al. (2025) Interactions between gut microbes and host promote degradation of various fiber components in Meishan pigs. *mSystems*, 10(2), e0150024.

Oh SY, et al. (2025) The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. *Cell reports. Medicine*, 6(2), 101929.

Zhuang Y, et al. (2025) Core microbe *Bifidobacterium* in the hindgut of calves improves the growth phenotype of young hosts by regulating microbial functions and host metabolism. *Microbiome*, 13(1), 13.

Venkatesan A, et al. (2025) Trichuriasis in Human Patients from Cote d'Ivoire Caused by Novel *Trichuris incognita* Species with Low Sensitivity to Albendazole/Ivermectin Combination Treatment. *Emerging infectious diseases*, 31(1), 104.

Polani R, et al. (2025) Cefiderocol Resistance Conferred by Plasmid-Located Ferric Citrate Transport System in KPC-Producing *Klebsiella pneumoniae*. *Emerging infectious diseases*, 31(1), 123.

Elias R, et al. (2025) Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity. *Cancer research communications*, 5(5), 743.